OBJECTIVE： To evaluate the effectiveness and safety of bromocriptine by vaginal delivery in the treatment of hyperprolactinemia in Chinese female patients， and to provide evidence-based reference for clinic. METHODS： Retrieved from PubMed， The Cochrane Liabrary， Excerpta Medica Database， Chinese Journal Full-text Database， Wanfang Database and China Bxdxiology Medicine disc， randomized controlled trials （RCTs） about bromocriptine oral tablets by vaginal delivery （trial group） vs. bromocriptine by oral administration （control group） in the treatment of bromocriptine in Chinese female patients were collected. After data extraction， quality evaluation of included studies with Cochrane system evaluator manual 5.1.0， Meta-analysis of serum level of Prolactin levels， the rate of menstruation improvement， the rate of pregnancy recovery， the rate of galactorrhea disappearance， the incidence of ADR in digestive tract and the incidence of ADR in nervous system was conducted by using Rev Man 5.1 statistical software. RESULTS： A total of 16 RCTs were included， involving 1 175 patients. The results of Meta-analysis showed that the incidence of ADR in digestive tract [OR＝0.14，95％CI（0.09， 0.23），P＜0.001] and ADR in nervous system [OR＝0.32，95％CI（0.11， 0.90），P＝0.03] in trial group were significantly lower than control group， with statistical significance. There was no statistical significance in serum level of PRL [MD＝0.24，95％CI （－0.94， 1.41），P＝0.69]， the rate of menstruation improvement [RD＝0.04，95％CI （－0.04， 0.11），P＝0.32]， the rate of pregnancy recovery [RD＝0.01，95％CI （－0.08， 0.10），P＝0.84] or the rate of galactorrhea disappearance [RD＝0.05，95％CI （－0.03， 0.13），P＝0.20] between 2 groups. CONCLUSIONS： Compared with oral administration， bromocriptine by vaginal delivery has no significant difference in therapeutic efficacy but has obvious advantages in the incidence of ADR in digestive tract and in nervous system and better safety. It is suggested to development the special vaginal delivery preparation of bromocriptine.